Page last updated: 2024-10-15

neoechinulin

Description

neoechinulin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135540424
MeSH IDM0064575

Synonyms (12)

Synonym
neoechinulin
25644-25-1
piperazinetrione, ((2-(1,1-dimethyl-2-propenyl)-6-(3-methyl-2-butenyl)-1h-indol-3-yl)methylene)-, (z)-
UMQMXLLNFXQTIE-LDADJPATSA-N
neoechinuline
piperazinetrione, [[2-(1,1-dimethyl-2-propenyl)-6-(3-methyl-2-butenyl)-1h-indol-3-yl]methylene]-
piperazinetrione, [[2-(1,1-dimethyl-2-propenyl)-6-(3-methyl-2-butenyl)-1h-indol-3-yl]methylene]-, (z)-
2,3,5-piperazinetrione, 6-[[2-(1,1-dimethylallyl)-6-(3-methyl-2-butenyl)indol-3-yl]methylene]-
(6e)-6-([2-(1,1-dimethyl-2-propenyl)-6-(3-methyl-2-butenyl)-1h-indol-3-yl]methylene)-2,3,5-piperazinetrione #
alkaloid e 9, from aspergillus amstelodami
AKOS030213207
mfcd08274587

Research Excerpts

Overview

Neoechinulin is an indole alkaloid and has a double bond between C8/C9, which tends to contribute to its cytoprotective nature.

ExcerptReference
"Neoechinulin is an indole alkaloid and has a double bond between C8/C9, which tends to contribute to its cytoprotective nature."( Neoechinulins: Molecular, cellular, and functional attributes as promising therapeutics against cancer and other human diseases.
Anand, U; Behl, T; Dey, A; Ghosh, A; Jha, NK; Kumar, M; Mitra, S; Mundhra, A; Proćków, J; Sanyal, R, 2022
)

Treatment

ExcerptReference
"Co-treatment with neoechinulin A, but not neoechinulin A pre-treatment before rotenone exposure, significantly impeded cell death by rotenone."( Neoechinulin a impedes the progression of rotenone-induced cytotoxicity in PC12 cells.
Akashi, S; Arai, T; Kimura, T; Kobayashi, S; Kuramochi, K; Sugawara, F; Takeuchi, T; Watanabe, N, 2011
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (20.00)29.6817
2010's6 (60.00)24.3611
2020's2 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]